Related Experiment Videos
Dose intensity in small cell lung cancer
N Thatcher1, S M Lee, P J Woll
1CRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK.
Seminars in Oncology
|May 13, 1998
Summary
Higher-dose, accelerated chemotherapy regimens significantly improve patient survival. Novel methods using peripheral blood progenitor cells offer easier delivery of dose-intensive chemotherapy for better treatment outcomes.
Area of Science:
- Oncology
- Pharmacology
Background:
- Dose intensity is crucial for effective cancer treatment.
- Preclinical models and clinical trials highlight the importance of dose intensity.
Purpose of the Study:
- To review evidence on the importance of dose intensity in cancer treatment.
- To discuss novel methods for delivering dose-intensive chemotherapy.
Main Methods:
- Review of preclinical models and clinical trial data.
- Analysis of recent randomized trials evaluating chemotherapy regimens.
- Evaluation of peripheral blood progenitor cell autotransfusions for dose intensification.
Main Results:
- Statistically significant survival benefits observed with higher-dose, accelerated chemotherapy.
- Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) can be used with these regimens.
- Peripheral blood progenitor cells enable easier delivery of dose-intensive chemotherapy.
Conclusions:
- Dose-intensive chemotherapy, particularly accelerated regimens, improves survival outcomes.
- Peripheral blood progenitor cell autotransfusions represent a practical advancement in delivering dose-intensive chemotherapy.
- These findings support the use of intensified chemotherapy strategies for better cancer treatment.